Until recently, warfarin had been the only treatment option for long-term oral anticoagulation of patients.However, warfarin therapy is challenging because of marked interindividual variability in dose and response, requiring frequent monitoring and dose titration.These limitations have prompted the clinical development of new oral anticoagulant. Recently, New oral anticoagulant, dabigatran (direct thrombin inhibitor), and rivaroxaban (factor Xa inhibitors) have gained regulatory approval as alternative therapies to warfarin in Turkey.This review provides a concise remark for clinicians that evaluated the efficacy and safety of these drugs, their pharmacokinetic and pharmacodynamic properties, and a practical approach to their clinical use
Alan : Sağlık Bilimleri
Dergi Türü : Ulusal
Benzer Makaleler | Yazar | # |
---|
Makale | Yazar | # |
---|